Bloomberg News

Pharmasset Rises on Positive Results for Hepatitis C Drug

September 30, 2011

Sept. 30 (Bloomberg) -- Pharmasset Inc. shares rose to the highest in more than four years after the drugmaker’s PSI-7977 medication was shown effective at treating hepatitis C.

Pharmasset, based in Princeton, N.J., gained $5.07, or 6.6 percent, to $82.37 at 4 p.m. in Nasdaq Stock Market trading. It is the highest share price since April 2007.

--Editor: Andrew Pollack

To contact the reporter on this story: Chris Staiti in Boston at cstaiti@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Tim Cook's Reboot
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus